These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2241194)

  • 1. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
    Yoshimoto M
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of tumor marker CA15-3 in breast cancer].
    Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
    Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
    Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of tumor markers in breast cancer patients].
    Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CA15-3 tumor marker in early detection of breast cancer].
    Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
    Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
    Barak V; Carlin D; Sulkes A; Treves A; Biran S
    Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
    Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
    Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of tumor markers in lung cancer management].
    Ariyoshi Y; Kuwabara M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3020-6. PubMed ID: 2823721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
    Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
    Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
    Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
    Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.